EA201791100A1 - METHOD OF OBTAINING A PARENTAL COMPOSITION BASED ON ANIDULAFUNGIN - Google Patents

METHOD OF OBTAINING A PARENTAL COMPOSITION BASED ON ANIDULAFUNGIN

Info

Publication number
EA201791100A1
EA201791100A1 EA201791100A EA201791100A EA201791100A1 EA 201791100 A1 EA201791100 A1 EA 201791100A1 EA 201791100 A EA201791100 A EA 201791100A EA 201791100 A EA201791100 A EA 201791100A EA 201791100 A1 EA201791100 A1 EA 201791100A1
Authority
EA
Eurasian Patent Office
Prior art keywords
anidulafungin
composition based
obtaining
pharmaceutical composition
invention describes
Prior art date
Application number
EA201791100A
Other languages
Russian (ru)
Inventor
Митеш Натаварлал Пател
Мафатлал Трибховандас Даве
Пранавкумар Джаиеш Чокси
Original Assignee
Гуфик Байосайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гуфик Байосайенсиз Лимитед filed Critical Гуфик Байосайенсиз Лимитед
Publication of EA201791100A1 publication Critical patent/EA201791100A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Настоящее изобретение описывает сублимированный, не содержащий мицеллообразующего поверхностно-активного вещества фармацевтический состав на основе анидулафунгина, а также подходящий солюбилизирующий агент и подкислитель для парентерального введения. Фармацевтический состав обеспечивает достаточную солюбилизацию и стабилизацию анидулафунгина, увеличивая, таким образом, срок годности, и снижает вероятность осаждения во время хранения. Далее, изобретение описывает способ его получения.The present invention describes a sublimated, micelle-forming surfactant-free pharmaceutical composition based on anidulafungin, as well as a suitable solubilizing agent and acidifier for parenteral administration. The pharmaceutical composition provides sufficient solubilization and stabilization of anidulafungin, thus increasing the shelf life, and reduces the likelihood of precipitation during storage. Further, the invention describes a method for its production.

EA201791100A 2014-11-19 2015-09-07 METHOD OF OBTAINING A PARENTAL COMPOSITION BASED ON ANIDULAFUNGIN EA201791100A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3668MU2014 2014-11-19
PCT/IN2015/000349 WO2016079749A2 (en) 2014-11-19 2015-09-07 Process for preparation of parenteral formulation of anidulafungin

Publications (1)

Publication Number Publication Date
EA201791100A1 true EA201791100A1 (en) 2017-11-30

Family

ID=56014644

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791100A EA201791100A1 (en) 2014-11-19 2015-09-07 METHOD OF OBTAINING A PARENTAL COMPOSITION BASED ON ANIDULAFUNGIN

Country Status (4)

Country Link
EP (1) EP3220954A4 (en)
EA (1) EA201791100A1 (en)
WO (1) WO2016079749A2 (en)
ZA (1) ZA201703330B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100335122C (en) * 1999-03-03 2007-09-05 伊莱利利公司 Echinocandin pharmaceutical formulations containing micelle-forming surfactants
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
RS62583B1 (en) * 2010-06-29 2021-12-31 Merck Sharp & Dohme Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin

Also Published As

Publication number Publication date
EP3220954A2 (en) 2017-09-27
ZA201703330B (en) 2019-07-31
WO2016079749A2 (en) 2016-05-26
WO2016079749A3 (en) 2016-07-21
EP3220954A4 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
PT3271316T (en) Stabilisation of 1-chloro-3,3,3-trifluoropropene
MX370611B (en) Methods useful in the synthesis of halichondrin b analogs.
EA201791117A1 (en) PARTIAL AGONISTS INSULIN RECEPTOR
DOP2016000262A (en) SOLID DISPERSION AMORPHES UNDERSTANDING TAXANE, COMPRESSED UNDERSTANDING THE SAME, AND METHOD FOR THEIR PREPARATION
CY1125150T1 (en) PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS
EA201700019A1 (en) HIGHLY PURE ORIENTATION AND METHOD FOR ITS OBTAINING
EA201591758A1 (en) Sub-ADAMTS13 INTRODUCTION
MX2018005785A (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof.
MX2016011938A (en) Liquid pharmaceutical composition.
IN2014CH00840A (en)
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
CL2016001745A1 (en) -3'-methyl-abscisic acid (s) and esters thereof
NZ733451A (en) Combination therapy for pulmonary hypertension
EP3193610A4 (en) Selective nav1.7 inhibitors for the treatment of diabetes
WO2016009225A3 (en) Method for preventing or treating a protein aggregation disease
EA201791100A1 (en) METHOD OF OBTAINING A PARENTAL COMPOSITION BASED ON ANIDULAFUNGIN
MX2021003230A (en) Pharmaceutical compositions comprising meloxicam.
EA201792417A1 (en) LYOPHYLIZED PHARMACEUTICAL COMPOSITION OF RIFABUTIN AND METHOD FOR ITS PREPARATION
MX2016013979A (en) New administration routes of insulin, insulin analogs or derivatives of insulin.
Betelli et al. " Bologna
TR201618030T2 (en) Tastedly corrected paracetamol formulations.
酒井洋輔 et al. CHIMASKI NEW JEWELRY" TIME"
花菇 Happy NEW YEAR
Trajković Šetnja gradom